



**LEI: 549300Q7EXQQH6KF7Z84**

31 May 2024

**RTW Biotech Opportunities Ltd**  
(the "Company")

**Transaction in Own Shares**

The Company announces that on 30 May 2024 it bought back 200,000 of its own shares, to be held as treasury shares, at an average price \$1.42 per share.

Further details are set out below:

Number of shares held as treasury shares following this purchase: 10,053,791.

Total shares in issue excluding treasury shares following this purchase: 335,913,649.

The Company has bought back these shares under the authority granted by shareholders at its Annual General Meeting in May 2024, which permits the Company to repurchase a maximum of 14.99% of its ordinary shares. The actual number of shares repurchased by the Company will depend on market conditions. This authority lasts until the next shareholder authority granted (expected to be at the Annual General Meeting in 2025), or until expressly revoked by shareholders.

The above figure of 335,913,649 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

No maximum consideration payable has been determined by the Company, but the Company is unable to pay a price for any shares pursuant to the buyback which would equate to a premium to the net asset value. It is the Company's current intention to hold any shares bought back in treasury.

The Company has instructed Numis Securities Limited as its broker in respect of its buyback transactions. This arrangement is in accordance with the UKLA Listing Rules and the Company's general authority to repurchase shares.

**For Further Information:**

**RTW Investments, LP**

**+44 (0)20 7959 6361**

**biotechopportunities@rtwfunds.com**

Woody Stileman, Managing Director  
Krisha McCune, Director, Investor Relations

**About RTW Biotech Opportunities Ltd:**

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at [www.rtwfunds.com/rtw-biotech-opportunities-ltd](http://www.rtwfunds.com/rtw-biotech-opportunities-ltd) for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

POSURVVRSRUVOAR